Tuesday, July 07, 2015 10:40:47 PM
UCLA research finds that the phenomenon takes a large toll on health care system
Enrique Rivero | July 07, 2015
The Affordable Care Act created several national initiatives aimed at reducing hospital readmission rates for heart attacks, congestive heart failure and other common high-risk conditions. But there is still no national program intended to address sepsis, a potentially life-threatening illness caused by infection.
Now, a new UCLA study found that sepsis accounts for roughly the same percentage of hospital readmissions in California as heart attacks and congestive heart failure — and that it costs the health care system more than both of them combined.
The research, conducted by the UCLA Clinical and Translational Science Institute is published online in the peer-reviewed journal Critical Care Medicine.
“Our study shows how common sepsis readmissions are and some of the factors that are associated with higher risk of readmission after these severe infections,” said Dr. Dong Chang, assistant professor of medicine at Harbor–UCLA Medical Center and the study’s lead author. “In addition, we show that sepsis readmissions have a significant impact on health care expenditures relative to other high-risk conditions that are receiving active attention and interventions.
“Based on these results, we believe that sepsis readmissions are under-recognized and should be among the conditions that are targeted for intervention by policymakers.”
The researchers analyzed admissions for adults 18 and older for sepsis at all California hospitals from 2009 through 2011, and during the same period for congestive heart failure and heart attacks. There were a total of 240,198 admissions for sepsis, 193,153 for congestive heart failure and 105,684 for heart attacks.
They found that the all-cause 30-day readmission rate for sepsis was 20.4 percent. The rates for congestive heart failure and heart attacks were 23.6 percent and 17.7 percent, respectively.
The study found that people with sepsis were readmitted because of respiratory failure; pneumonia; complications with devices, implants or grafts; urinary tract infections; renal infections; renal failure; and intestinal infections; among other causes.
It also revealed that readmission rates were higher among young adults than older adults, among men than women, among black and Native American patients than other racial groups, and among lower-income patients than those with higher incomes. In addition, people with other concurrent health problems were more likely to be readmitted than those with sepsis alone.
The estimated annual cost of sepsis-related readmissions in California during the study period was $500 million, compared with $229 million for congestive heart failure and $142 million for heart attacks.
“These findings suggest that efforts to reduce hospital readmissions need to include sepsis prominently, at least on par with heart failure and myocardial infarction,” said Dr. Martin Shapiro, chief of the UCLA Division of General Internal Medicine and Health Services Research at the David Geffen School of Medicine at UCLA, and the study’s primary investigator.
The next stage of the research will be to examine why patients are readmitted after sepsis and the percentage of those readmissions that are due to processes that can be improved upon, such as discharge practices, follow-up care and teaching patients how to take their medications.
The authors note some limitations to the study. For instance, they used claims data based on hospital codes for patient diagnoses; there is little research into the accuracy of this coding comparing congestive heart failure and heart attacks to sepsis. In addition, the analysis was limited to California hospitals, and the data may vary in other regions.
The study was funded by the National Institutes of Health (UL1TR000124) and the UCLA Clinical and Translational Science Institute. Chi-Hong Tseng of UCLA was a study co-author.
Hospital readmissions for sepsis are highly common, extremely costly | UCLA
http://newsroom.ucla.edu/releases/hospital-readmissions-for-sepsis-are-highly-common-extremely-costly
Recent CTSO News
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
- CytoSorbents to Report Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 10/27/2023 11:00:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM